Navigation Links
Advanced Life Sciences to Host Conference Call to Discuss Data From,Cethromycin's First of Two Phase 3 Pneumonia Trials

CHICAGO, June 29, 2007 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced that it will host a conference call and live webcast at 10:00 am (EDT) on Monday, July 2, 2007 to discuss data from Trial CL-06, the first of two pivotal Phase 3 clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day antibiotic, for the treatment of community acquired pneumonia (CAP).

Conference Call Details:

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website http://www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 800-561-2601(domestic) or 617-614-3518 (international). The passcode for the conference call is 84510433. A replay of the conference call will be available until August 2, 2007. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 90055877.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forw
'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
6. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Post Your Comments:
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
(Date:12/25/2014)... Phoenix, AZ (PRWEB) December 25, 2014 ... comes to outstanding customer service and affordable quality regarding ... metropolitan area announces recognition in 2014 by the “Queen ... and Sons has earned an impressive reputation over the ... pricing on a wide range of contractor services for ...
(Date:12/24/2014)... December 25, 2014 Epigenetics finds applications ... research, including oncology, drug discovery, developmental biology, and research ... as one of the most widely used techniques for ... GLOBOCAN, the prevalence of cancer is rapidly growing worldwide. ... 8.2 million cancer deaths, and 32.6 million people living ...
(Date:12/24/2014)... 24, 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... tort litigation currently underway in Pennsylvania’s Philadelphia Court of ... December 24, 2014, court documents indicate that 1,183 claims ... individuals who developed gynecomastia (male breast growth) and other ... Court indicates that this represents an increase of more ...
(Date:12/24/2014)... December 24, 2014 The federal ... allege the blood thinner caused life-threatening episodes of ... leadership structure for the proceeding, Bernstein Liebhard LLP ... the Court plans to select lawyers to serve ... plans on appointing a Plaintiffs’ Steering Committee, which ...
(Date:12/24/2014)... 2014 The report “Stivarga (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... a drug which is used in the treatment of ... and is also prescribed to patients who suffer from ... approved is a multi-kinase inhibitor and it blocks many ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... Financing Provides Capital to Complete EVEREST Pivotal Study and Begin ... European Commercialization ... Investors, MENLO PARK, Calif., Dec. 4 Evalve, Inc., the leader ... that it had successfully completed a $60 million Series D,financing. BBT Fund ...
... Bivalirudin lowers bleeding risk for patients undergoing bypass, study ... newer kind of anticlotting drug is safe over the ... heart attacks. , The drug, a "direct thrombin inhibitor" ... during cardiac procedures such as bypass surgery. , "We ...
... some truth to the popular wisdom that plump babies are ... people who had a low birth weight are more likely ... found that even people who had just mild or moderate ... smaller babies than those who had better mental health, said ...
... of New Orleans residents in months after the disaster, study ... the people living in New Orleans and about one-quarter of ... signs of a mood or anxiety disorder five to seven ... Researchers surveyed 1,043 residents in Louisiana, Alabama and Mississippi. , ...
... TARRYTOWN, N.Y., Dec. 4 EpiCept Corporation,(Nasdaq and OMX ... offering of 3,333,333 million shares of its common stock ... to approximately 1,666,667,million shares of common stock at an ... $4.7 million in net proceeds from the,offering. Rodman & ...
... Nabi,Biopharmaceuticals (Nasdaq: NABI ) announced ... assets constituting its Biologics strategic business unit ... of Biotest,AG, for $185 million in cash. ... has acquired or will acquire the Biologics ...
Cached Medicine News:Health News:UPDATED: Evalve(R) Completes $60 Million Series D Financing 2Health News:UPDATED: Evalve(R) Completes $60 Million Series D Financing 3Health News:Newer Anticlotting Drug Safe, Effective for Heart Surgeries 2Health News:Newer Anticlotting Drug Safe, Effective for Heart Surgeries 3Health News:Smaller babies more prone to depression, anxiety later on 2Health News:Many Katrina Survivors Suffered Psychological Symptoms 2Health News:EpiCept Corporation Announces Pricing of Public Offering 2Health News:EpiCept Corporation Announces Pricing of Public Offering 3Health News:Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG 2Health News:Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG 3
... & Nephew offers a wide variety of ... available in both partially threaded and fully ... are the 5.5 and 7.0 mm products. ... the surgeon's job a little easier. Ratchet ...
... Nailing System is one of the first ... for either an antegrade or a retrograde ... , ,Stryker Orthopaedics Trauma has now created ... together all the capabilities and benefits of ...
... Humeral Nail System has been designed to ... noninvasive treatments have historically failed to give ... blend of strength and flexibility. Ideally suited ... titanium alloy is twice that of stainless ...
... nailing techniques have largely replaced the use of plates ... The use of rods or pins in the forearm ... has been no way to lock the pins or ... a non-locked nail is back out of the implant. ...
Medicine Products: